Form 4: CARLSMED Chief IP Officer Niall Casey Reports Significant Equity Transactions

CARLSMED, Inc.'s Chief IP Officer and Director, Niall Casey, reported the acquisition of 3,612 common shares through preferred stock conversion and a grant of 53,571 stock options.

Summary

• Niall Casey, Chief IP Officer, Secretary, and Director of CARLSMED, INC. [CARL], reported two significant equity transactions.
• On July 24, 2025, 3,612 shares of preferred stock were converted into an equal number of common shares immediately prior to the Issuer's initial public offering (IPO) closing, without additional consideration.
• On July 22, 2025, Mr. Casey was granted 53,571 stock options with an exercise price of $15 per share and an expiration date of July 9, 2035.
• These newly granted stock options will vest in equal quarterly installments over four years, starting from July 22, 2025, contingent on Mr. Casey's continuous service.
• Following these transactions, Mr. Casey directly beneficially owns 937,585 shares of common stock and 166,049 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports standard insider equity transactions (stock option grant and preferred stock conversion) which are generally neutral to slightly positive as they align management incentives with shareholder interests. No negative information is disclosed.

Positives

• The grant of 53,571 stock options to a key officer and director aligns management's long-term interests with those of shareholders, incentivizing performance.
• The conversion of preferred stock to common stock simplifies the company's capital structure, a common and positive step often associated with an IPO.

Future Outlook

The unvested stock options will vest over a four-year period, indicating a continued commitment and incentive structure for the reporting person.

Industry Context

This filing is a standard disclosure of an insider's equity transactions and does not provide broader industry context or trends.

Related Party Transactions

• Grant of 53,571 stock options to Niall Casey, a Director and Chief IP Officer.
• Conversion of 3,612 shares of preferred stock held by Niall Casey into common stock.

Stakeholder Impact

• Shareholders: The grant of stock options could lead to future dilution if exercised, but also aligns management incentives with shareholder value creation. The conversion of preferred stock to common simplifies the capital structure.

Next Steps

• The unvested stock options will continue to vest in equal installments on each quarterly anniversary of July 22, 2025, over the next four years, provided continuous service.

Key Dates

Keywords

CARLSMED, CARL, Form 4, Insider Transaction, Stock Options, Preferred Stock Conversion, Common Stock, Equity Grant, Niall Casey, Chief IP Officer, Director